Pulmonology

New insights might help researchers improve the efficacy of LTA4H inhibitors.

A contributing mechanism responsible for the development of idiopathic pulmonary fibrosis has been identified.

A generic version of the 0.3 mg- and 0.15 mg-strength injectors has been approved for the treatment of patients that include those with life-threatening allergic reactions.

Experts argue that oral corticosteroids should be available at home for early use in asthma exacerbation.

The FDA has granted an orphan drug designation in a second indication to Martin Pharmaceuticals’ trimetazidine dihydrocholoride (LIVANTRA) for the treatment of pulmonary arterial hypertension (PAH).

Investigators find more evidence to support IgE as a reliable biomarker for targeted biologic therapy in asthma management.

The FDA has granted an orphan drug designation to Onspira Therapeutics’ OSP-101, the first and only inhaled interleukin-1 receptor antagonist (IL-1Ra) for the treatment of bronchiolitis obliterans.

In its phase 2 trial, acebilustat (CTX-4430) was found to show clinically meaningful improvement in pulmonary exacerbations in patients with cystic fibrosis.

New research outlines the role of neutrophil cytoplasts in severe asthma which could lead to new therapeutic pathways to treat the disease.

A study evaluating a home and community education program to improve asthma management among Head Start students with asthma found that a majority of families have insufficient availability of asthma medications in the home.

The FDA’s Antimicrobial Drugs Advisory Committee voted 12 to 2 in favor of the safety and efficacy of ALIS (amikacin liposome inhalation suspension) for difficult-to-treat patients with nontuberculous mycobacterial lung disease.

Researchers were surprised to see the relatively high rates of secondhand smoke-related respiratory symptoms, such as shortness of breath and wheezing, among adolescents without asthma.

Investigators have discovered a rare cell type, referred to as Foxi1+pulmonary ionocyte, which is thought to be a key player in the biology of cystic fibrosis.

The combined results of a recent meta-analysis and a new population-based study supports there being a significant association between asthma and ADHD.

Patients who received electronic asthma control plans had fewer asthma exacerbations, but more research is needed to find out how much of an impact such interventions have over time.

Three-quarters of patients with aspirin-exacerbated respiratory disease often have allergies to alcohol. A new study finds a common therapy for the one can also help the other.

In prior studies, younger populations that have asthma were not found to be impacted by autonomy preferences.

If these results are confirmed by future research, the use of blood eosinophil count tests could improve patient care and reduce asthma-associated healthcare costs.

A study of pediatric patients with asthma admitted to emergency departments has determined that while rhinovirus is the most prevalent infection, it is the non-rhinovirus pathogens that are associated with an increased absolute risk of treatment failure.

Proper diagnostics is key in healthcare, but patient education on management and medication use can lead to empowerment that unlocks optimal health outcomes.

The ACAAI's new yardstick for pediatric asthma provides guidance on stepping-up asthma treatments to gain and maintain symptom control.

Researchers found that tobacco users, regardless of what product-type they used, underestimated the risks nicotine exposure posed to children and the high rates of multiple tobacco use.

Results showed that participants with doctor-diagnosed asthma had a 38% increased risk of developing AF compared to those without asthma.

Analysis of data from the Danish Birth Registry showed that tonsillectomies were associated with nearly triple relative risk of disease of the respiratory tract.

The FDA agreed to remove a boxed warning from inhalant combinations of corticosteroid and long-acting beta-agonist following research from a collaboration of pharmaceutical manufacturers.